TrialLancet (London, England)2015

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Cornelia L Trimble et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.